TD Cowen Maintains Buy on AVITA Medical, Raises Price Target to $14

Benzinga · 1d ago
TD Cowen analyst Joshua Jennings maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $12 to $14.